Abstract: The invention concerns CD4+ T survivin epitopes and their vaccine and diagnostic uses.

Abstract: The invention relates to a peptide mixture including at least two different peptides from the hepatitis C virus (HCV), whereby at least one of them is a peptide from the C protein binding to at least four different HLA-II molecules, the occurrence of which exceeds 5% in the Caucasian population with a binding activity <1,000 nM. Said invention also relates to the applications thereof as a drug useful in the prevention and treatment of HCV infections or as a diagnostic reagent for HCV-specific T lymphocytes.

Abstract: The invention relates to a method of selecting HLA-DP4 ligand molecules comprising the following steps: (i) incubation of purified HLA-DP4 with a tracer having general formula (I) Z1X1X2X3X4X5X6X7X8X9Z2 (wherein Z1 and Z2, which may be identical or different, are equal to zero or each represent a peptide with between 1 and 100 amino acids; X6 represents an aromatic or hydrophobic amino acid or a cysteine; and X1 represents an aromatic or hydrophobic amino acid and/or X9 represents an aromatic or hydrophobic amino acid or C, D, Q, S, T or E; and X2,X3,X4,X5,X7 and X8 each represent an amino acid) in the presence of different concentrations of molecule(s) to be tested; (ii) separation of the different complexes formed; (iii) detection of HLA-DP4/peptide tracer complexes; and (iv) selection of ligand molecules having a binding capacity IC50<1000 nM. The invention also relates to the applications of same.

Abstract: The invention relates to a mixture of peptides originating from a Nef protein and the applications thereof as a medicine (in immunogenic compositions which stimulate the production in vivo of anti-HIV T CD4+ lymphocytes and are therefore useful for vaccinating against AIDS) or as a reactive diagnosis agent for T lymphocytes particular to HIV, particularly to assess the immune status of HIV-positive patients or patients undergoing anti-retroviral therapy. Each of said peptides in the mixture is linked to at least three HLA-DR molecules encoded by the alleles selected from the group comprising alleles HLA DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501 (molecules DR1, DR3, DR4, DR7, DR11, DR13 and DR15) and to at least one HLA-DR molecule encoded by the alleles selected from the group comprising alleles HLA DRB3*0101, DRB4*0101 and DRB5*0101 (B3, B4 and B5;), with a binding capacity of<1000 nM, said mixture of peptides linking all of the aforementioned alleles.

Abstract: The invention concerns peptides and proteins for desensitizing specifically the vast majority of subjects allergic to bee venom and compositions containing said peptides or proteins.